August 6, 2025
The ride continues
It’s a huge understatement to say that owning shares in Tandem is one hell of a thrill ride. In the first quarter the company anticipated full year sales between $997 million to $1.007 billion – today they narrowed that range to $1 billion with appx $700m million US and $300 million ex-US. A decrease from what they noted in the first quarter here in the US a slight increase internationally.
These results fall in line with how the market is changing here in the US. Beta Bionics is gaining traction while Sequel has begun marketing the twisst. As . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
